<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006009</url>
  </required_header>
  <id_info>
    <org_study_id>SUMC-NCI-102</org_study_id>
    <secondary_id>CDR0000068017</secondary_id>
    <secondary_id>NCI-102</secondary_id>
    <nct_id>NCT00006009</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma</brief_title>
  <official_title>A Phase I, Multiple Dose Escalation Trial of Intravenous Humanized Anti-CD3 Antibody (HuM291) in Patients With CD3+ T-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have advanced or recurrent lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of monoclonal antibody HuM291 in patients with&#xD;
           advanced or recurrent CD3+ T-cell lymphomas.&#xD;
&#xD;
        -  Evaluate the pharmacokinetics and pharmacodynamics of this treatment regimen in this&#xD;
           patient population.&#xD;
&#xD;
        -  Determine the response in these patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive monoclonal antibody HuM291 IV over 3 hours on days 1-4 in the absence of&#xD;
      unacceptable toxicity. Patients achieving a partial response, complete response with&#xD;
      recurrence, or stable disease may receive further therapy.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of monoclonal antibody HuM291 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed weekly for 1 month and then monthly for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>visilizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CD3+ T-cell lymphoma for which no standard curative therapy&#xD;
             exists&#xD;
&#xD;
               -  Peripheral T-cell lymphoma&#xD;
&#xD;
                    -  Recurrent and/or progressive disease after at least 1 prior therapy&#xD;
&#xD;
               -  Mycosis fungoides&#xD;
&#xD;
                    -  Stage IB/IIA&#xD;
&#xD;
                         -  Recurrent and/or progressive disease after at least 2 prior therapies&#xD;
&#xD;
                    -  Stage IIB-IVB&#xD;
&#xD;
                         -  Recurrent and/or progressive disease after at least 1 prior therapy&#xD;
&#xD;
               -  All other T-cell lymphomas&#xD;
&#xD;
                    -  Recurrent and/or progressive disease after at least 1 prior therapy&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
               -  Any nodal site or mass lesion at least 1.5 cm in longest axis on physical exam or&#xD;
                  CT scan&#xD;
&#xD;
               -  Skin lesions at least 1 cm in longest axis for cutaneous lymphoma&#xD;
&#xD;
          -  High numbers of circulating T-cells allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3*&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3* NOTE: * Unless due to lymphoma&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 times normal*&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal*&#xD;
&#xD;
          -  Hepatitis B and C negative NOTE: * Unless due to lymphoma&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other active malignancies except basal cell skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  HIV-1 negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 60 days since prior humanized or chimeric antibody therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior investigational drugs or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youn H. Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>October 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Visilizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

